Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idarubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | S100A4 | P26447 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idarubicin SCHEMBL3750 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL16606206 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL15159345 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL16609956 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL10061859 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL13488561 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL14071644 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL12257447 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL20541733 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL18738468 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838469-B2 | Pharmaceutical composition that exhibits reduced side-effects comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime and a pyrimidine derivative with known antitumor activity | N-GENE RESEARCH LABORATORIES INC. (US) | 2005-01-04 | — | — | US | disclosed |
| EP-0993304-B1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N GENE RES LAB INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030050345-A1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050345-A1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDGF, CA7 | TOP2A 333/4885MEN1 403/4885THRB 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.